Investor Relations

Latest Financial Results

Q2 2019

Quarter Ended Jun 30, 2019

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

Company Overview

H-CYTE was formed to build and develop a diversified portfolio of innovative medical technology products and services to improve quality of life for patients. The DenerveX ® System is H-CYTE’s first product and is intended to provide long-lasting relief from pain associated with facet joint syndrome. For biomedical services, H-CYTE manages Lung Health Institute. Lung Health Institute is a leader in regenerative medicine that specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases. In late 2019, H-CYTE’s biologics division, LungCYTE, plans to submit an IND to the FDA to study novel and proprietary biologics for treatment of COPD.

Investor Contact Information

Company

H-CYTE, Inc
201 E Kennedy Blvd
Suite 700
Tampa, FL 33602

Investor Relations

LR Advisors LLC
Jason Assad
President
2020 Stone Meadow Way
Cumming, GA 30041
T: (678) 570-6791
jassad@HCYTE.com

Transfer Agent

Interwest Transfer Co., Inc.
1981 Murray Holiday Rd
Ste 100
Salt Lake City, UT 84117
T: (801) 272-9294

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.